Literature DB >> 8494583

Biological activity of bacterial cell wall components. Immunogenicity of an immunostimulating bacterial extract.

W G Bessler1, E Sedelmeier.   

Abstract

An immunostimulating bacterial extract (IBE, Broncho-Vaxom) used for the prevention and treatment of recurrent respiratory tract infections consists of lyophilized fractions derived from 21 bacterial strains occurring in these infections. The immunogenic properties of IBE were determined in vivo in a murine model. It could be demonstrated that the extract constitutes an active immunogen in Balb/c mice. As shown by ELISA, IBE-specific antisera could be obtained after repeated i.p. immunizations; the antibodies were mainly of the IgG and IgM isotypes. The antibodies also bound - to a variable degree - to the bacterial strains used for the preparation of the extract. Additionally the antisera were shown to recognize the bacterial cell wall components porin, lipoprotein/lipopeptide and murein. Thus, IBE constitutes an active immunogen in vivo inducing antibodies directed against bacterial cell wall components; this could be of importance for understanding the therapeutic effect of the extract.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494583

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  In vitro Superoxide Production by Peripheral Neutrophils from Patients with Inflammatory Bowel Disease.

Authors:  O H Nielsen; D Berild; I Ahnfelt-Rønne
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

2.  Effects of the Bacterial Extract OM-85 on Phagocyte Functions and the Stress Response.

Authors:  S Baladi; S Kantengwa; Y R Donati; B S Polla
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

3.  IRF7-Associated Immunophenotypes Have Dichotomous Responses to Virus/Allergen Coexposure and OM-85-Induced Reprogramming.

Authors:  Emma de Jong; Jean-Francois Lauzon-Joset; Jonatan Leffler; Michael Serralha; Alexander N Larcombe; Claus T Christophersen; Patrick G Holt; Deborah H Strickland; Anthony Bosco
Journal:  Front Immunol       Date:  2021-07-22       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.